Grant: Alliance Grants
McMaster University
$30,000.00
Radiolabeling, in vivo imaging and biodistribution of Alpha Fetoprotein in COLO-205 cancer model
EF 2024-25
Résumé
Most cancer cells express alpha fetoprotein (AFP) receptors while healthy cells do not. By attaching a chemotherapy payload to AFP, Alpha Cancer Technologies Inc. (ACT) developed a targeted therapies platform to connect the chemotherapeutic agents to AFP to selectively deliver the therapies to tumors. Preclinical studies published by ACT in a high impact factor journal confirmed the selectively of AFP to cancer cells and delivered toxins to cancer and suppressor cells bypassing normal cells. This results in increased efficacy and a reduction of, or no toxicity.
Targeted radiopharmaceuticals utilize radiation to selectively target cancer cells. Non-invasive molecular imaging techniques such as positron emission tomography (PET) has gained notability for cancer detection. PET images generate physiological and functional information, which can be combined with anatomical information from CT. Encouraging results of the in vivo uptake of 125I-AFP and 131I-AFP in mammary carcinoma animal models demonstrated preferential uptake and internalization of AFP. Although these previous reports have highlighted the need and impact of molecular imaging with radiolabeled AFP constructs, radiolabeling with positron emitting radionuclides would have clear advantages in terms of resolution and quantification. Zirconium-89 (89Zr) is a PET radioisotope with a 78.4 h lifetime and 23% positron emission decay, which make it compatible with the biological half-life of most proteins. The first goal of this partnership is to radiolabel AFP with 89Zr and validate the resulting tracer for PET imaging. The second goal is to prepare the radioligand therapeutic (RLT) agent through Lutetium-177 (177Lu) labeling of AFP. 177Lu is a radioisotope for targeted radiotherapy due to its nuclear properties, which provide high beta energy efficiency. When used to label disease-targeting molecules, 177Lu can deliver radiation to cancer cells while minimizing damage to healthy surrounding tissue.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
597565-2024
Name nom
Sadeghi, Saman S
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
9100
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Recherche biomédicale
Research subject fr
Biomedical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Radiolabeling, in vivo imaging and biodistribution of Alpha Fetoprotein in COLO-205 cancer model
Keywords
molecular imaging; nuclear medicine; radiopharmaceuticals; radiotherapy
Application summary
Most cancer cells express alpha fetoprotein (AFP) receptors while healthy cells do not. By attaching a chemotherapy payload to AFP, Alpha Cancer Technologies Inc. (ACT) developed a targeted therapies platform to connect the chemotherapeutic agents to AFP to selectively deliver the therapies to tumors. Preclinical studies published by ACT in a high impact factor journal confirmed the selectively of AFP to cancer cells and delivered toxins to cancer and suppressor cells bypassing normal cells. This results in increased efficacy and a reduction of, or no toxicity.
Targeted radiopharmaceuticals utilize radiation to selectively target cancer cells. Non-invasive molecular imaging techniques such as positron emission tomography (PET) has gained notability for cancer detection. PET images generate physiological and functional information, which can be combined with anatomical information from CT. Encouraging results of the in vivo uptake of 125I-AFP and 131I-AFP in mammary carcinoma animal models demonstrated preferential uptake and internalization of AFP. Although these previous reports have highlighted the need and impact of molecular imaging with radiolabeled AFP constructs, radiolabeling with positron emitting radionuclides would have clear advantages in terms of resolution and quantification. Zirconium-89 (89Zr) is a PET radioisotope with a 78.4 h lifetime and 23% positron emission decay, which make it compatible with the biological half-life of most proteins. The first goal of this partnership is to radiolabel AFP with 89Zr and validate the resulting tracer for PET imaging. The second goal is to prepare the radioligand therapeutic (RLT) agent through Lutetium-177 (177Lu) labeling of AFP. 177Lu is a radioisotope for targeted radiotherapy due to its nuclear properties, which provide high beta energy efficiency. When used to label disease-targeting molecules, 177Lu can deliver radiation to cancer cells while minimizing damage to healthy surrounding tissue.